BR112015029530A8 - métodos para tratamento de condições inflamatórias utilizando s-[4-(3-fluoro-3-metilbutiriloxi)but-2-inil] 6\alpha, 9\alpha-difluoro-17\alpha-(furan-2-il)carboniloxi-11\beta-hidroxi-16\alpha-metil-3-oxoandrosta-1, 4-dieno-17\beta-carbotioato. - Google Patents

métodos para tratamento de condições inflamatórias utilizando s-[4-(3-fluoro-3-metilbutiriloxi)but-2-inil] 6\alpha, 9\alpha-difluoro-17\alpha-(furan-2-il)carboniloxi-11\beta-hidroxi-16\alpha-metil-3-oxoandrosta-1, 4-dieno-17\beta-carbotioato. Download PDF

Info

Publication number
BR112015029530A8
BR112015029530A8 BR112015029530A BR112015029530A BR112015029530A8 BR 112015029530 A8 BR112015029530 A8 BR 112015029530A8 BR 112015029530 A BR112015029530 A BR 112015029530A BR 112015029530 A BR112015029530 A BR 112015029530A BR 112015029530 A8 BR112015029530 A8 BR 112015029530A8
Authority
BR
Brazil
Prior art keywords
alpha
oxoandrosta
methylbutyryloxy
carbothioate
carbonyloxy
Prior art date
Application number
BR112015029530A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015029530A2 (pt
Inventor
Trinadha Rao Chitturi
Sanjivkumar Sheth Gaurav
Chimanlal Patel Gopalkumar
Ranchhodbhai Patel Jiten
Thennati Rajamannar
Nandlal Mandhane Sanjay
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of BR112015029530A2 publication Critical patent/BR112015029530A2/pt
Publication of BR112015029530A8 publication Critical patent/BR112015029530A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR112015029530A 2013-05-28 2014-05-28 métodos para tratamento de condições inflamatórias utilizando s-[4-(3-fluoro-3-metilbutiriloxi)but-2-inil] 6\alpha, 9\alpha-difluoro-17\alpha-(furan-2-il)carboniloxi-11\beta-hidroxi-16\alpha-metil-3-oxoandrosta-1, 4-dieno-17\beta-carbotioato. BR112015029530A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1881MU2013 2013-05-28
PCT/IN2014/000359 WO2014192027A1 (en) 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Publications (2)

Publication Number Publication Date
BR112015029530A2 BR112015029530A2 (pt) 2017-07-25
BR112015029530A8 true BR112015029530A8 (pt) 2019-12-17

Family

ID=51300796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029530A BR112015029530A8 (pt) 2013-05-28 2014-05-28 métodos para tratamento de condições inflamatórias utilizando s-[4-(3-fluoro-3-metilbutiriloxi)but-2-inil] 6\alpha, 9\alpha-difluoro-17\alpha-(furan-2-il)carboniloxi-11\beta-hidroxi-16\alpha-metil-3-oxoandrosta-1, 4-dieno-17\beta-carbotioato.

Country Status (18)

Country Link
US (1) US9458187B2 (https=)
EP (1) EP3004133B1 (https=)
JP (1) JP6366696B2 (https=)
KR (1) KR20160030085A (https=)
CN (1) CN105431445A (https=)
AU (1) AU2014272640B2 (https=)
BR (1) BR112015029530A8 (https=)
CA (1) CA2912400A1 (https=)
EA (1) EA027831B9 (https=)
ES (1) ES2664019T3 (https=)
IL (1) IL242658A0 (https=)
MX (1) MX2015016283A (https=)
MY (1) MY179214A (https=)
PH (1) PH12015502652A1 (https=)
SG (1) SG11201509680TA (https=)
UA (1) UA117248C2 (https=)
WO (1) WO2014192027A1 (https=)
ZA (1) ZA201508640B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015016283A (es) 2013-05-28 2016-03-11 Sun Pharma Advanced Res Co Ltd METODOS PARA TRATAR AFECCIONES INFLAMATORIAS UTILIZANDO S-[4-(3-FLUORO-3-METILBUTIRILOXI) BUT-2-INIL] 6A, 9A-DIFLUORO-17A- (FURAN-2-IL) CARBONILOXI-11ß-HIDROXI-16A - METIL-3-OXOANDROSTA-1,4-DIEN-17ß - CARBOTIOATO.
EP3250582A4 (en) * 2015-01-31 2018-09-26 Sun Pharma Advanced Research Company Ltd Crystalline form of s-(4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl)6alpha,9alpha-difluoro-17alpha,-(furan-2-yl)carbonyloxy-11beta-hydroxy-16alpha-methy1-3-oxoandrosta-1,4-diene-17beta-carbothioate
CN106279341A (zh) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 一种糠酸氟替卡松的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
WO2004001369A2 (en) 2002-06-20 2003-12-31 Sun Pharmaceutical Industries Limited Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
TWI374147B (en) * 2006-01-27 2012-10-11 Sun Pharma Advance Res Company Ltd Novel 11β-hydroxyandrosta-4-ene-3-ones
MX2015016283A (es) 2013-05-28 2016-03-11 Sun Pharma Advanced Res Co Ltd METODOS PARA TRATAR AFECCIONES INFLAMATORIAS UTILIZANDO S-[4-(3-FLUORO-3-METILBUTIRILOXI) BUT-2-INIL] 6A, 9A-DIFLUORO-17A- (FURAN-2-IL) CARBONILOXI-11ß-HIDROXI-16A - METIL-3-OXOANDROSTA-1,4-DIEN-17ß - CARBOTIOATO.

Also Published As

Publication number Publication date
MY179214A (en) 2020-11-02
EA027831B1 (ru) 2017-09-29
UA117248C2 (uk) 2018-07-10
ZA201508640B (en) 2017-09-27
JP6366696B2 (ja) 2018-08-01
EP3004133B1 (en) 2018-03-07
PH12015502652A1 (en) 2016-03-07
US20160102117A1 (en) 2016-04-14
WO2014192027A1 (en) 2014-12-04
SG11201509680TA (en) 2015-12-30
CN105431445A (zh) 2016-03-23
CA2912400A1 (en) 2014-12-04
AU2014272640A1 (en) 2015-11-26
MX2015016283A (es) 2016-03-11
US9458187B2 (en) 2016-10-04
EP3004133A1 (en) 2016-04-13
EA201592283A1 (ru) 2016-04-29
ES2664019T3 (es) 2018-04-18
KR20160030085A (ko) 2016-03-16
AU2014272640B2 (en) 2018-04-05
BR112015029530A2 (pt) 2017-07-25
EA027831B9 (ru) 2017-12-29
JP2016520122A (ja) 2016-07-11
IL242658A0 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
AR128748A2 (es) Compuestos sustituidos de aminopurina, sus composiciones y métodos de tratamiento con ellos
MX380092B (es) Tratamiento de la osteoartritis.
BR112018016433A2 (pt) inibidores de heteroarila de pad4
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
EA201690669A1 (ru) Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
BR112016000975A8 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
BR112015017878A2 (pt) composto da fórmula estrutural ii, composto da fórmula estrutural iii, composição farmacêutica e método de tratamento de um distúrbio mediado por vmat2
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA201690094A1 (ru) Ингибиторы syk
BR112016008593A8 (pt) composto, composição farmacêutica, método de regulação de transcrição gênica em uma célula, uso de um composto e método de inibição de reconhecimento mediado por bromodomínio de uma região de acetil lisina de uma proteína
EA201891553A1 (ru) Ингибиторы syk
UY35300A (es) Formulación de combinación de dos compuestos antivirales
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
IN2015DN00370A (https=)
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
BR112015029462A8 (pt) Inibidores de quinase
MX340928B (es) Derivados de oxazolina e isoxazolina como moduladores de canales de calcio de liberación activa (crac).
BR112017022281A2 (pt) métodos para tratar câncer
BR112017003663A2 (pt) composto, composição, e, método para tratamento de infecção por hiv.
MX374758B (es) Inhibidores de tirosina cinasa de bruton.
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]